Brad Rodu Says Declining Cigarette Smoking Is Key to Tobacco Harm Reduction | 2Firsts Interview

Nov.20
Brad Rodu Says Declining Cigarette Smoking Is Key to Tobacco Harm Reduction | 2Firsts Interview
After more than 30 years researching tobacco harm reduction, University of Louisville professor Brad Rodu says opposition to smoke-free alternatives still surprises him. In an exclusive 2Firsts interview in Manila, he argued that declining smoking rates represent progress even if nicotine use rises, discussed nicotine and cancer, and examined Sweden's snus experience and youth vaping. Rodu welcomed recent FDA decisions but criticized slow reviews and poor risk communication. He called a change in the WHO's stance potentially significant, while doubting it would happen soon.

Cover image: Brad Rodu speaks at a harm reduction event in Manila, Philippines, in November 2026. (Photo: 2Firsts)

Key Points

30 Years of Research: Rodu said continued opposition to lower-risk tobacco alternatives remains his biggest surprise. He considers declining cigarette smoking progress even if nicotine use increases.

Nicotine and Cancer: Rodu argued that nicotine itself does not cause cancer in humans. Separate research reviewed by 2Firsts identified increased risks for certain cancers among snus users.

Sweden's Experience: Rodu highlighted historical differences in smoking, snus use and lung cancer mortality between Swedish men and women.

Youth Vaping: Rodu urged nicotine pouch manufacturers to prevent underage use, while arguing that responsibility also extends to parents and young people.

FDA and WHO: Rodu welcomed recent FDA decisions but criticized slow reviews and inadequate risk communication. He expressed little optimism about a near-term change in WHO's stance.

2Firsts

Nov. 20, 2026

Philip Morris International (PMI) held its Technovation Manila event in the Philippines on November 10, drawing approximately 550 attendees for discussions on tobacco harm reduction, scientific research and smoke-free innovation.

In an exclusive interview with 2Firsts on the sidelines of the event, Brad Rodu, professor emeritus at the University of Louisville School of Medicine, said declining cigarette smoking represented public-health progress even if the use of other nicotine products increased.

Trained in oral pathology and with a background in cancer research, Rodu held an endowed chair in tobacco harm reduction research at the University of Louisville from 2005 to 2025. He has studied tobacco harm reduction for more than three decades, focusing on the health implications of replacing cigarettes with smokeless alternatives and contributing to scientific and policy discussions in the field.

During the interview, Rodu discussed nicotine and cancer, Sweden's experience with snus, youth vaping in the United States, recent regulatory decisions by the U.S. Food and Drug Administration (FDA), and the future of tobacco harm reduction.

Reflecting on his research career since the 1990s, Rodu said he was surprised by continued opposition to alternatives he considered substantially less harmful than cigarettes.

"What surprises me most is the opposition to a much safer form of using tobacco," he said.

Declining Smoking, Nicotine and Cancer Risks

Asked how public-health progress should be measured if cigarette smoking declines while the use of other nicotine products increases, Rodu questioned whether continued nicotine use among adults should necessarily be viewed as a problem.

"I don't see a problem with uptake of safer nicotine products if smoking goes to near zero," he said.

Rodu argued that the major diseases associated with cigarette smoking were not directly caused by nicotine itself. He compared nicotine with caffeine, saying the two substances had similarities in their effects, although they were not identical.

He said the main historical difference lay in how the two substances were consumed: caffeine through drinks and nicotine predominantly through burning tobacco and inhaling smoke.

According to the FDA, cigarette smoke contains more than 7,000 chemicals, including over 70 that can cause cancer.

"But nicotine itself is not dangerous. It's addictive," Rodu said.

Rodu said smokers who were already dependent on nicotine should move to less harmful delivery systems rather than continue inhaling cigarette smoke.

Asked about differing scientific views on nicotine and cancer, Rodu referred to epidemiological studies of Swedish men who used snus, a form of oral smokeless tobacco.

He said those studies had not shown higher cancer rates among snus users than among non-users. He also questioned whether findings from laboratory experiments involving cells could be directly applied to humans.

"Nicotine itself does not cause cancer in humans. We don't have any evidence for that," he said.

Following the interview, Rodu told 2Firsts by email that he was not aware of epidemiological studies specifically examining nicotine itself and cancer. He provided reviews of smokeless tobacco and cancer, including a 2009 systematic review by Peter Lee and Jan Hamling.

Separately, 2Firsts reviewed a 2023 systematic review published in the International Journal of Cancer. It reported evidence of increased risks for certain cancers among exclusive Swedish snus users, with the certainty of the findings varying from moderate to very low. The review assessed snus use, not nicotine exposure in isolation.

https://wdcdn.qpic.cn/MTY4ODg1NTQyNjMwMzkzMQ_377313_-qMGES5tWFp8acfa_1795184771?w=1300&h=880&type=image/png
Smoking, snus use and dual use among men and women aged 25–64 in northern Sweden, 1986–2009. The figures are from the Northern Sweden MONICA surveys and are not national estimates. (Source: Rodu et al., Scandinavian Journal of Public Health, 2013, Figure 1.)

Sweden's Snus Experience and Lung Cancer Trends

Rodu said his interest in Sweden developed while reviewing historical lung cancer mortality statistics from the World Health Organization (WHO).

He described lung cancer as a "sentinel disease" of smoking, explaining that mortality trends could provide insights into a population's historical smoking patterns.

Reviewing statistics dating back to 1950, he noticed that Swedish men had comparatively low lung cancer mortality rates.

Rodu believed the pattern was related to lower cigarette smoking and the longstanding use of snus among Swedish men.

"I must go to Sweden to understand why," he recalled thinking.

In 2002, Rodu undertook a research sabbatical in Sweden, working with Swedish collaborators to investigate tobacco use and smoking-related diseases.

In a 2009 study co-authored with Philip Cole, which Rodu provided to 2Firsts after the interview, the researchers compared lung cancer mortality across 25 European Union countries using data from around 2002.

The study reported an age-standardized lung cancer mortality rate of 77 deaths per 100,000 among Swedish men aged 45 and older, compared with 166 across the countries studied.

In the same comparison, Swedish women's lung cancer mortality rate was the sixth-highest among the 25 countries studied.

Rodu pointed to historical differences in smoking and snus use between Swedish men and women as an important part of his interpretation. He said Swedish women had traditionally smoked more and used snus less frequently than men, although more women were now using snus and nicotine pouches.

A separate 2013 study by Rodu and colleagues documented low smoking prevalence alongside snus use in two northern Swedish counties.

The 2013 paper disclosed that Rodu's research was supported by unrestricted grants to the University of Louisville from Swedish Match, Reynolds American, Altria and British American Tobacco, as well as by the Kentucky Research Challenge Trust Fund. The authors said the tobacco manufacturers had no role in that study.

Rodu viewed Sweden's experience as evidence of the potential for smokeless tobacco products to help reduce cigarette smoking. The historical population comparisons, however, do not by themselves establish how much of the decline was caused by snus.

https://wdcdn.qpic.cn/MTY4ODg1NTQyNjMwMzkzMQ_746014_2oRNRRVs84kAeTtf_1795184896?w=634&h=832&type=image/png
Historical lung cancer mortality trends among men aged 45 and older in Sweden and other European countries, 1950–2004. The comparison does not, on its own, establish a causal effect of snus on lung cancer mortality. (Source: Rodu and Cole, Scandinavian Journal of Public Health, 2009, Figure 1.)

Youth Vaping Offers Lessons for Nicotine Pouches

Asked what the nicotine pouch industry should learn from the rise of vaping, Rodu pointed to controversy over adolescent e-cigarette use in the United States.

He said opposition to vaping had been driven largely by concerns about teenage use.

Rodu acknowledged that youth vaping increased sharply in 2018 and 2019 before declining in subsequent years. He believed much of the earlier increase was probably temporary rather than evidence of lasting nicotine dependence.

"It was more experimentation," he said.

Rodu nevertheless emphasized the importance of preventing underage use of tobacco and nicotine products.

He said nicotine pouch manufacturers should seek to prevent substantial uptake among teenagers, as manufacturers of other tobacco products should.

However, he argued that responsibility did not rest exclusively with manufacturers.

"My opinion is that teen use of tobacco is not exclusively an industry issue," he said.

Rodu said parents and teenagers themselves also had responsibilities. While adolescents frequently experimented with behaviors associated with adulthood, he said society should continue working to protect children.

Rodu Sees FDA Progress but Calls for Better Risk Communication

Asked about recent FDA decisions involving nicotine products, Rodu said the agency appeared to be making greater use of scientific evidence when evaluating smoke-free alternatives.

On October 30, the FDA authorized the marketing of 24 VELO nicotine pouch products through its premarket tobacco product application (PMTA) pathway.

Earlier, on June 30, the agency authorized 20 ZYN nicotine pouch products to be marketed with a specific modified-risk claim. Those products had already received authorization for sale in January 2025.

Commenting on the FDA's recent decisions, Rodu described the agency's efforts to use scientific evidence to authorize smoke-free products as positive steps. He made clear, however, that he had no inside information about its decision-making.

He nevertheless criticized the pace of FDA reviews, arguing that smokers needed access to a wider range of alternatives.

Rodu said a limited selection would not satisfy all smokers, whose preferences for different products varied.

He also called on the FDA to improve public education about the relative health risks of tobacco and nicotine products.

Rodu said the agency had not done enough to help Americans and healthcare professionals understand those differences, although he was encouraged by indications that the FDA's Center for Tobacco Products was giving greater attention to public education.

Tobacco Companies, WHO and the Future of Harm Reduction

Asked where major tobacco companies were falling short in their efforts to reduce smoking-related harm, Rodu declined to offer specific recommendations about corporate strategy.

He said his expertise concerned tobacco-related health, disease and mortality rather than business management.

"I couldn't possibly claim to have any experience in managing a tobacco company," he said.

Nevertheless, Rodu viewed tobacco companies' investment in smoke-free products positively.

"I see progress when tobacco companies are interested in smoke-free products," he said.

He suggested that major companies increasingly recognized the long-term decline of cigarette sales and were developing alternatives for smokers.

Turning to the next five years, Rodu identified a potential change in WHO's position on tobacco harm reduction as one of the most significant developments that could occur.

He argued that WHO's stance influenced tobacco policy discussions in many countries, including decisions affecting access to products he considered less harmful than cigarettes.

"I think the biggest thing that could happen would be a change in the WHO's attitude," he said.

Rodu also pointed to the United Kingdom, Japan and Sweden as markets where the adoption of alternative nicotine products had accompanied declines in cigarette sales.

He cited approximately 18 million e-cigarette users in the United States.

A 2026 study published in NEJM Evidence, which Rodu provided to 2Firsts after the interview, estimated that 17.79 million U.S. adults used e-cigarettes every day or on some days in 2024, based on the National Health Interview Survey.

Rodu said he believed such international trends would eventually make it harder for WHO to disregard tobacco harm reduction.

However, he saw little indication that WHO's position would change in the near future and expressed doubt that a meaningful shift would occur soon.

2FIRSTS | Japanese Addiction Psychiatrist Says Complete Abstinence Is Not Always the Goal of Harm Reduction | 2Firsts Interview
2FIRSTS | Japanese Addiction Psychiatrist Says Complete Abstinence Is Not Always the Goal of Harm Reduction | 2Firsts Interview
Complete abstinence is not always the goal of addiction treatment under a harm-reduction approach, Japanese psychiatrist Tomohiro Shirasaka told 2Firsts in Manila. In the interview, he discussed patients' quality of life, Japan's shift towards heated tobacco products, and the challenges of quitting smoking for people with mental illness. Drawing on addiction treatment work in the Philippines, he advocated support rather than punishment and questioned whether fear-based health warnings effectively address the reasons people continue smoking.
www.2firsts.com


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

German Customs Seize 115,800 Vapes in €1.4 Million Tax Case
German Customs Seize 115,800 Vapes in €1.4 Million Tax Case
Germany's Magdeburg Main Customs Office seized 115,800 untaxed e-cigarettes containing a combined 4.366 million mL of e-liquid during four truck inspections between August 10 and September 4, 2026. The seizures prevented an estimated €1.397 million in tax losses and set a record for the customs office's jurisdiction. Criminal proceedings have been initiated against four truck drivers. The case follows a separate German investigation involving more than 7.6 million illicit vapes and an estimated €33.3 million in excise-tax losses.
Enforcement
Oct.13
Special Report|Japan Tobacco Buys CLEW: Can Its 160,000-Store Cigarette Network Help It Vie for U.S. Nicotine Pouch Share Against PMI and BAT?
Special Report|Japan Tobacco Buys CLEW: Can Its 160,000-Store Cigarette Network Help It Vie for U.S. Nicotine Pouch Share Against PMI and BAT?
Japan Tobacco Inc. (JT) announced on November 12, 2026, that it had acquired the U.S. assets of nicotine pouch brand CLEW from Nevcore Innovations Inc., including trademarks, intellectual property, product formulations and a Premarket Tobacco Product Application (PMTA). CLEW, currently distributed through selected outlets in 13 U.S. states, will immediately join the JTI LIGGETT portfolio. The transaction follows JT's approximately $2.4 billion acquisition of U.S. cigarette maker Vector Group in 2024. JTI LIGGETT says its existing cigarette brands reach more than 160,000 U.S. retail stores. During the 2026 NACS Show in October, JTI LIGGETT booth staff told 2Firsts that the company had not yet launched nicotine pouches in the United States. Although Nevcore previously announced FDA acceptance of CLEW's PMTA, the brand is absent from the agency's current list of authorized nicotine pouch products. JT has not disclosed a retail expansion plan for CLEW.
Business
Nov.12
US ITC Judge Finds Glas Infringed Two JUUL Vape Patents, Recommends Restrictions on Related Imports——Glas Received FDA Marketing Authorization for Four Vape Pods in May 2026; Proposed Restrictions Remain Under Commission Review
US ITC Judge Finds Glas Infringed Two JUUL Vape Patents, Recommends Restrictions on Related Imports——Glas Received FDA Marketing Authorization for Four Vape Pods in May 2026; Proposed Restrictions Remain Under Commission Review
A U.S. International Trade Commission (USITC) administrative law judge issued an initial determination on October 20, 2026, finding that certain Glas vaping devices, cartridges and components infringed 12 claims across two patents asserted by JUUL, constituting a violation of Section 337 of the Tariff Act of 1930. The judge recommended a limited exclusion order and a cease and desist order against the Glas respondents. Five months earlier, the FDA authorized four Glas e-cigarette pods, including mango, blueberry and two menthol variants. The patent investigation concerns device and cartridge structures and is separate from FDA premarket review. The proposed import restrictions have not become final, and their product-level scope remains unresolved.
company
Nov.05
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23
Italian Financial Police Seize 4.3 Million E-Cigarettes and Smoking Accessories; 28 Reported to Judicial Authorities Across Operations
Italian Financial Police Seize 4.3 Million E-Cigarettes and Smoking Accessories; 28 Reported to Judicial Authorities Across Operations
Italy's Guardia di Finanza announced on October 28 that officers in Latina province had seized approximately 4.3 million e-cigarettes and smoking accessories at an unauthorized warehouse in an operation involving restrictions on the possession and sale of tobacco-related products. Another 300,000 suspected counterfeit or unsafe items were confiscated during separate inspections, bringing total seizures across the operations to more than 4.6 million products. Twenty-eight people were reported to judicial authorities over suspected smuggling and counterfeiting offenses. Officials did not disclose separate vape quantities, the value of the merchandise or alleged violations associated with individual brands.
Enforcement
Oct.29
Imperial Brands Plans to Cut Nearly 18% of Workforce as German Plant Closure and Polish Outsourcing Drive Restructuring
Imperial Brands Plans to Cut Nearly 18% of Workforce as German Plant Closure and Polish Outsourcing Drive Restructuring
Imperial Brands disclosed on November 17, 2026, that its global manufacturing and organisational restructuring is expected to reduce between 4,200 and 4,600 roles by the end of 2030, equivalent to approximately 16%–18% of its workforce at the end of 2025. The first phase covers 2,100 roles with departures confirmed or subject to consultation, while a further 2,100–2,500 positions are expected to be eliminated by 2030. The company is proceeding with the closure of its Langenhagen factory in Germany, has sold its manufacturing facility in Taiwan, and has transferred selected finance, procurement and supply-chain operations in Poland to Capgemini. The restructuring programme is expected to cost approximately £740 million, with Imperial targeting at least £320 million in annual cost savings by 2030.
company
Nov.18